cbdMD, Inc. to Host Conference Call to Discuss September 30, 2023 Fourth Quarter and Fiscal Year 2023 Results
Charlotte, North Carolina–(Newsfile Corp. – December 20, 2023) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation’s leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Friday December 22, 2023, to discuss the company’s September 30, 2023 fourth quarter of fiscal 2023 and full year of fiscal 2023 financial results and business progress.
CONFERENCE CALL DETAILS
| Friday December 22 2023, 4:20 p.m. Eastern Time | ||
| USA/Canada: | 800-319-4610 | |
| International: | 604-638-5340 | |
| Teleconference Replay dial in: | ||
| USA/Canada: | 855-669-9658 | |
| International: | 412-317-0088 | |
| Replay Passcode: | 0614 | |
| Webcast/Webcast Replay link – available through December 22, 2024: | ||
| https://www.gowebcasting.com/13114 | ||
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and recognized hemp-derived cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products as well as Full Spectrum and Delta 9 THC products. The cbdMD brand currently includes high-quality, premium CBD products including tinctures, gummies, topicals, capsules, sleep aids and more. The Company’s Paw CBD brand includes formulated pet products including tinctures, chews and topicals in varying strengths. To learn more about cbdMD and the complete line of products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook or visit one of the thousands of retail outlets that carry cbdMD products.
Forward-Looking Statements
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our clinical studies, and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022 as filed with the Securities and Exchange Commission (the “SEC”) on December 15, 2022 and amended on December 20, 2022 and May 3, 2023 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
1 THC-free is defined as below the level of detection using validated scientific analytical tools.
Contact Information:
cbdMD, Inc.
Ronan Kennedy, Interim CEO and CFO
+1 (704) 445-3064
IR@cbdmd.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/191815
